J&J's Esketamine, at current price, is 'low value for money' — ICER
For Johnson & Johnson’s $JNJ pharmaceutical version of the hallucinogenic anesthetic ketamine — esketamine — to be cost-effective for use in treatment-resistant depression in the long …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.